$23,285.85 consulting Payment -- Roche/Genentech to Dr. Daniel White
Ophthalmologist Daniel White Receives Significant Consulting Fee from Roche/Genentech
This page provides a detailed analysis of a $23,285.85 consulting payment from Roche/Genentech to Dr. Daniel White. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $23,285.85 |
| Payment Type | consulting |
| Payment Nature | Consulting Fee |
| Pharmaceutical Company | Roche/Genentech |
| Physician | Dr. Daniel White |
| NPI Number | 1221253181 |
| Physician Specialty | Ophthalmology |
| Location | Albany, NY |
| Date of Payment | 2024-10-19 |
| Related Drug/Device | Eliquis |
| Conflict Assessment | High -- Significant |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Roche/Genentech made a $23.3K consulting payment to Daniel White, a Ophthalmology specialist in Albany, NY. The payment was associated with Eliquis. Daniel White received a $23,285.85 consulting fee from Roche/Genentech on October 19, 2024. The payment was related to consulting services, not directly for prescribing or promoting a specific drug. The payment amount is substantial for a single consulting engagement.
Patient Guidance: What This Payment Means for You
If you are a patient, this payment relates to a doctor's professional services for consulting, not directly for prescribing medication. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Consulting fees for physicians can vary widely based on expertise and the scope of work, but this amount is on the higher end for a single engagement in ophthalmology.
Regulatory Context: Sunshine Act Requirements
Physicians must disclose payments from pharmaceutical companies to ensure transparency in healthcare and prevent potential conflicts of interest.
Related Topics
This payment is related to the following healthcare transparency topics:
- consulting-fees
- pharma-payments
- roche-genentech
- daniel-white
- ophthalmology
- eliqius
Understanding consulting Payments
Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.
Frequently Asked Questions About This Payment
What was this $23.3K payment for?
This was a consulting payment of $23.3K from Roche/Genentech to Daniel White, categorized as "Consulting Fee". It was associated with Eliquis. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Daniel White accept pharmaceutical money?
Yes, Daniel White received this $23.3K payment from Roche/Genentech. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Daniel White's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this consulting payment?
A consulting payment of $23.3K may reflect legitimate advisory services the physician provides. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Ophthalmology?
To compare this payment against Ophthalmology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Ophthalmology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Daniel White's relationship with Roche/Genentech?
The payment is categorized as a 'Consulting Fee' under 'consulting' payment type. This $23.3K consulting payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Ophthalmology?
The specific drug mentioned, Eliquis, is typically associated with cardiovascular conditions, not ophthalmology.
What should patients do after learning about this payment?
If you are a patient, this payment relates to a doctor's professional services for consulting, not directly for prescribing medication.
What else should I know about this consulting payment?
The payment date is in the future, suggesting this might be a pre-scheduled or reported future engagement.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.